CA-125 Result Interpretation
This CA-125 value of 13.0 U/mL is normal and does not suggest ovarian cancer, but the notation "in the Presence of HAMA" is a critical laboratory flag indicating potential assay interference that requires careful clinical correlation.
Understanding the Result
Your CA-125 level falls well within the normal reference range (0-38.1 U/mL). According to ESMO guidelines, CA-125 is elevated in approximately 85% of patients with advanced ovarian cancer, but this marker has significant limitations 1:
- Not specific to ovarian cancer: Can be elevated in benign conditions (endometriosis, ovarian cysts) and other malignancies
- Less sensitive in early disease: Only elevated in ~50% of FIGO stage I ovarian cancer cases
- Age and menopausal status matter: Interpretation varies by clinical context
The HAMA Issue: Critical Caveat
The laboratory specifically noted "in the Presence of HAMA" (Human Anti-Mouse Antibodies), which is a red flag for potential assay interference. Here's what this means:
What is HAMA?
HAMA are human immunoglobulins that develop against mouse antibodies, typically after:
- Exposure to mouse monoclonal antibodies used in imaging studies
- Therapeutic monoclonal antibody treatments
- Sometimes spontaneously
How HAMA Affects CA-125 Measurements
Research demonstrates that HAMA can cause both falsely elevated and falsely lowered CA-125 results 2, 3, 4:
- Most commonly causes falsely elevated values when HAMA binds to the mouse antibodies used in the CA-125 immunoassay
- Can persist for weeks to months after exposure to mouse antibodies 2
- Standard blocking agents (adding mouse IgG to the assay) may not eliminate interference, especially with anti-idiotypic antibodies 4
Key finding: One study showed CA-125 values up to 221 U/mL due to HAMA interference in a patient with completely normal ovaries 3.
Clinical Action Plan
1. Determine HAMA Source
Ask the patient about:
- Prior imaging studies using mouse monoclonal antibodies (immunoscintigraphy)
- Any therapeutic monoclonal antibody treatments
- Timing of any such exposures (HAMA typically transient, resolving after 8-24 weeks) 2
2. If Clinical Suspicion for Ovarian Cancer Exists
Do NOT rely on this CA-125 result alone. The ESMO guidelines emphasize that imaging is superior to CA-125 for diagnosis 1:
- Obtain transvaginal and transabdominal ultrasound by an expert examiner
- Use IOTA Simple Rules or ADNEX models (superior to CA-125 for distinguishing benign from malignant masses)
- Consider CT thorax/abdomen/pelvis if ultrasound suggests malignancy
- If mucinous histology suspected, add CEA and CA 19-9 levels
3. If HAMA Interference Suspected
Options to obtain accurate CA-125:
- Repeat testing using a different assay platform that uses different antibodies 3
- Request affinity chromatography to remove HAMA before measurement 5, 4 (though not routinely available)
- Wait 8-24 weeks and retest if HAMA exposure was recent 2
4. Clinical Context Matters
For a 53-year-old woman (perimenopausal/postmenopausal age):
- If symptomatic (abdominal/pelvic pain, bloating, urinary frequency, early satiety): Proceed directly to imaging regardless of CA-125 value 1
- If asymptomatic screening: This normal value is reassuring, but CA-125 is not recommended for screening in average-risk women
Bottom Line
Your CA-125 level is numerically normal, but the HAMA notation means this result may be unreliable. If there is any clinical concern for ovarian cancer based on symptoms or examination findings, proceed directly to pelvic ultrasound with IOTA risk assessment, as imaging is more accurate than CA-125 for diagnosis 1. Do not let a "normal" CA-125 in the presence of HAMA provide false reassurance if clinical suspicion exists.